CD226 and neoplasm: Given the critical role of the CD155/TIGIT/DNAM-1 axis in modulating immune responses within the tumor microenvironment, and the potential concern that CAR-T cell engagement of CD155 might interfere with these regulatory pathways, we next investigated whether CD155 CAR-T cells disrupt CD155’s interaction with its native cognate immune ligands.